logo-loader
viewImmunoPrecise Antibodies Ltd

ImmunoPrecise Antibodies on an aggressive sales and business development drive

ImmunoPrecise Antibodies Ltd's (CVE:IPA) president and chief executive Jennifer Bath caught up with Proactive Investors at the Spring Investor Summit 2019 in New York City.

Operating from their laboratory facilities at the Vancouver Island Technology Park in Victoria, British Columbia …  ImmunoPrecise is an 'end-to-end' provider for accelerated antibody research and discovery.

Quick facts: ImmunoPrecise Antibodies Ltd

Price: 0.63 CAD

TSX-V:IPA
Market: TSX-V
Market Cap: $42.83 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of ImmunoPrecise Antibodies Ltd named herein, including the promotion by the Company of ImmunoPrecise Antibodies Ltd in any Content on the Site,...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Full interview: CytoDyn CEO says leronlimab shrunk tumor in first...

CytoDyn Inc (OTCMKTS:CYDY) CEO Nader Pourhassan tells Proactive the first patient of a new Phase 1b/2 clinical trial for its metastatic triple-negative breast cancer treatment leronlimab reported encouraging initial results. Pourhassan says the Vancouver, Washington-based biotechnology...

5 hours, 26 minutes ago

2 min read